Sulfuric Acid

Sulfuric Acid

SCHEMBL1256454

CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC.O=S(=O)([O-])[O-].[H+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.50
DNM1 Q05193 10/20 0.48
HTT P42858 2/20 0.48
SLC22A1 O15245 1/20 0.46
KMT2A Q03164 1/20 0.44
APAF1 O14727 1/20 0.44
HSP90AA1 P07900 1/20 0.44
RAD52 P43351 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ALOX12 P18054 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HIF1A Q16665 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL6257862 1.00 LSS (0.50) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL2544112 1.00 LSS (0.50) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL6054967 1.00 LSS (0.50) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL6261097 1.00 LSS (0.50) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL6405436 1.00 LSS (0.50) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL31472472 0.98 LSS (0.52) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL29702366 0.98 LSS (0.52) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL4151447 0.98 LSS (0.52) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL2995826 0.98 LSS (0.52) LSSDNM1HTTSLC22A1KMT2A
Sulfuric Acid SCHEMBL29702465 0.98 LSS (0.52) LSSDNM1HTTSLC22A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229195-A1 RADIOLABELLED COMPOUNDS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-11-06 WO claimed
US-20250043039-A1 HALOGEN RECOVERY WITH OXIDANT AND PHASE TRANSFER CATALYST IN A PROCESS FOR HALOGENATING UNSATURATED ISOOLEFIN COPOLYMER ARLANXEO SINGAPORE PTE. LTD. (SG) 2025-02-06 US claimed
EP-4448595-A1 HALOGEN RECOVERY WITH OXIDANT AND PHASE TRANSFER CATALYST IN A PROCESS FOR HALOGENATING UNSATURATED ISOOLEFIN COPOLYMER Arlanxeo Singapore Pte. Ltd. (SG) 2024-10-23 EP claimed
WO-2024081696-A2 COMPOSITIONS CONTAINING PHASE CHANGE MATERIALS, METHODS FOR FORMING OBJECTS USING THE SAME, AND METHOD FOR USING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2024-04-18 WO claimed
WO-2023108259-A1 HALOGEN RECOVERY WITH OXIDANT AND PHASE TRANSFER CATALYST IN A PROCESS FOR HALOGENATING UNSATURATED ISOOLEFIN COPOLYMER ARLANXEO SINGAPORE PTE. LTD. (SG) 2023-06-22 WO claimed
CN-115232058-A Synthesis method of gliclazide intermediate 1,2-cyclopentanedicarboxamide 上海巽田科技股份有限公司 2022-10-25 CN claimed
CN-105980391-B Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds 昂皮瑞科公司 2021-09-03 CN claimed
CN-112608227-A Method for preparing isononanoic acid from isononanol through green oxidation 广东石油化工学院 2021-04-06 CN claimed
US-10265692-B2 Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds EMPIRIKO CORPORATION (US) 2019-04-23 US claimed
US-20160365228-A1 COMPONENT OF A PLASMA PROCESSING APPARATUS HAVING A PROTECTIVE IN SITU FORMED LAYER ON A PLASMA EXPOSED SURFACE LAM RESEARCH CORPORATION 2016-12-15 US claimed
WO-2015089089-A1 EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS EMPIRIKO CORPORATION (US) 2015-06-18 WO claimed
US-20140335698-A1 COMPONENT OF A PLASMA PROCESSING APPARATUS HAVING A PROTECTIVE IN SITU FORMED LAYER ON A PLASMA EXPOSED SURFACE LAM RESEARCH CORPORATION (US) 2014-11-13 US claimed
US-7696366-B2 Production process of bifunctional epoxy monomer by selective oxidation of diolefin compound SHOWA DENKO K.K. (JP) 2010-04-13 US claimed
US-7541312-B2 Porous carbons from carbohydrates TDA RESEARCH, INC. (US) 2009-06-02 US claimed
EP-1725497-A4 POROUS CARBONS FROM CARBOHYDRATES TDA RESEARCH INC (US) 2008-11-05 EP claimed
EP-1725497-A2 POROUS CARBONS FROM CARBOHYDRATES TDA RESEARCH, INC. (US) 2006-11-29 EP claimed
US-20060216828-A1 Rapid-response reversible dry surface CO2 detector MERCURY ENTERPRISE, INC. 2006-09-28 US claimed
WO-2005089145-A2 POROUS CARBONS FROM CARBOHYDRATES TDA RESEARCH, INC. (US) 2005-09-29 WO claimed
US-20050207962-A1 Porous carbons from carbohydrates TDA RESEARCH, INC. (US) 2005-09-22 US claimed
US-20050208248-A1 Automotive fuel hose and method for producing the same TOKAI RUBBER INDUSTRIES, LTD. (JP) 2005-09-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10265692-B2 Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds CYP3A43, CYP3A4, CYP2D6 LSS 476/4885DNM1 1942/4885HTT 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.